American Journal of Cardiovascular Drugs

, Volume 2, Issue 2, pp 77–89

Antihypertensive Drugs

An Overview
  • C. Venkata S. Ram
Therapy in Practice


For most patients with systemic hypertension, long-term drug treatment is indicated and is beneficial. There is overwhelming evidence to suggest that antihypertensive drugs offer protection against complications of hypertension. Whereas nondrug therapeutic options should be implemented in all patients, a vast majority will require pharmacological treatment to achieve goal blood pressure levels. Fortunately, a number of drugs are available to accomplish successful treatment of hypertensive disorders.

While it is conventional to initiate treatment with a single drug, a suitable combination of drugs is often required to control the blood pressure effectively. Although diuretics and β-blockers are effective and well tolerated, other classes of drugs are being increasingly used as the initial choice of therapy for hypertension. Every class of antihypertensive drugs offer advantages and some disadvantage; the physician should weigh the benefits and risks in selecting one drug over another. While the clinical parameters are followed in the management of patients with hypertension, it is also necessary to monitor the patients’ biochemical profile periodically in order to modify and adjust the therapy accordingly. A careful selection of drug therapy along with close follow-up offers the best prospect to reduce the burden of morbidity and mortality in hypertension. This article provides an overview of drugs in the management of patients with hypertension.


  1. 1.
    Joint National Committee. The sixth report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure (JNC VI). Arch Intern Med 1997; 157: 2413–46CrossRefGoogle Scholar
  2. 2.
    Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998; 339: 1957–63PubMedCrossRefGoogle Scholar
  3. 3.
    Agarwal R, Ram CVS. Diuretics. In: Singh BN, Dzau VJ, Vanhoute PM, editors. Cardiovascular pharmacology and therapeutics. New York: Churchill Livingstone, 1994; 319: 353–68Google Scholar
  4. 4.
    Brater DC. Pharmacology of diuretics. Am J Med Sci 2000; 319: 38–50PubMedCrossRefGoogle Scholar
  5. 5.
    LaCroix AZ, Ott SM, Ichikawa L, et al. Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. Ann Intern Med 2000; 133: 516–26PubMedGoogle Scholar
  6. 6.
    Ram CVS, Garrett BN, Kaplan NM. Moderate sodium restriction and various diuretics in the treatment of hypertension: effects on potassium wastage and blood pressure control. Arch Intern Med 1981; 141(8): 1015–9PubMedCrossRefGoogle Scholar
  7. 7.
    Greenberg A. Diuretic complications. Am J Med Sci 2000; 319: 10–24PubMedCrossRefGoogle Scholar
  8. 8.
    Grossman E, Messerli FH, Goldbourt U. Does diuretic therapy increase the risk of renal cell carcinoma? Am J Cardiol 1999; 83: 1090–3PubMedCrossRefGoogle Scholar
  9. 9.
    Freemantle N, Cleland J, Young P, et al. β-blockade after myocardial infarction. BMJ 1999; 318: 1730–7PubMedCrossRefGoogle Scholar
  10. 10.
    Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339: 489–97PubMedCrossRefGoogle Scholar
  11. 11.
    Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trials comparing β-blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999; 281: 1927–36PubMedCrossRefGoogle Scholar
  12. 12.
    Jamerson K, Dequattro V. The impact of ethnicity on response to antihypertensive therapy. Am J Med 1996; 101 Suppl. 3A: S22–32CrossRefGoogle Scholar
  13. 13.
    Lardinois CK, Neuman SL. The effects of antihypertensive agents on serum lipids and lipoproteins. Arch Intern Med 1988; 148: 1280–8PubMedCrossRefGoogle Scholar
  14. 14.
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. JAMA 2000; 283: 1967–75CrossRefGoogle Scholar
  15. 15.
    Ram CVS, Anderson RJ, Hart GR, et al. Alpha-adrenergic blockade by Prazosin in therapy of essential hypertension. Clin Pharmacol Ther 1981; 29(6): 719–22PubMedCrossRefGoogle Scholar
  16. 16.
    Rabkin SW. Mechanisms of action of adrenergic receptor blockers on lipids during antihypertensive drug treatment. J Clin Pharmacol 1993; 33: 286–91PubMedGoogle Scholar
  17. 17.
    Messerli FH. Implications of discontinuation of doxazosin arm of ALLHAT. Lancet 2000; 355: 863–4PubMedCrossRefGoogle Scholar
  18. 18.
    Grubb BP, Sirio C, Zelis R. Intravenous labetalol in acute aortic dissection. JAMA 1987; 258: 78–9PubMedCrossRefGoogle Scholar
  19. 19.
    Clark JA, Zimmerman HJ, Tanner LA. Labetalol hepatotoxicity. Ann Intern Med 1990; 113: 210–3PubMedGoogle Scholar
  20. 20.
    Langley MS, Heel RC. Transdermal clonidine. Drugs 1988; 35: 123–42PubMedCrossRefGoogle Scholar
  21. 21.
    Ram CVS, Holland OB, Fairchild C, et al. Withdrawal syndrome following cessation of guanabenz therapy. J Clin Pharmacol 1979; 19: 148–50PubMedGoogle Scholar
  22. 22.
    Ram CVS, Engelman K. Abrupt discontinuation of clonidine therapy. JAMA 1979; 242(19): 2104–5PubMedCrossRefGoogle Scholar
  23. 23.
    Bhatia BB. On the use of rauwolfia serpentina in high blood pressure. J Ind Med Assoc 1942; 11: 262–5Google Scholar
  24. 24.
    Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation 1998; 97: 1411–20PubMedCrossRefGoogle Scholar
  25. 25.
    Ram CVS. Captopril. Arch Intern Med 1982; 142(5): 914–6PubMedCrossRefGoogle Scholar
  26. 26.
    Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–53CrossRefGoogle Scholar
  27. 27.
    Saunders E, Weir MR, Kong BW, et al. A comparison of the efficacy and safety of a β-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990; 150: 1707–13PubMedCrossRefGoogle Scholar
  28. 28.
    Schrier RW, Estacio RO. Additional follow-up from the ABCD trial in patients with type 2 diabetes and hypertension. [letter] N Engl J Med 2000; 343: 1969PubMedCrossRefGoogle Scholar
  29. 29.
    Elliott WJ. Higher incidence of discontinuation of angiotensin converting enzyme inhibitors due to cough in black subjects. Clin Pharmacol Ther 1996; 60: 582–8PubMedCrossRefGoogle Scholar
  30. 30.
    Herings RMC, de Boer A, Stricker BHCH, et al. Hypoglycemia associated with use of inhibitors angiotensin converting enzyme. Lancet 1995; 345: 1194–8CrossRefGoogle Scholar
  31. 31.
    Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine. Arch Intern Med 2000; 160: 685–93PubMedCrossRefGoogle Scholar
  32. 32.
    Burnier M. Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355: 637–45PubMedCrossRefGoogle Scholar
  33. 33.
    Conlin PR, Spence JD, Williams B, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000; 13: 418–26PubMedCrossRefGoogle Scholar
  34. 34.
    Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205–51PubMedGoogle Scholar
  35. 35.
    Toto R, Schultz P, Raij L, et al. Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Hypertension 1998; 31: 684–91PubMedCrossRefGoogle Scholar
  36. 36.
    Bakris GL, Siamos M, Richardson D, et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. Kidney Int 2000; 58: 2084–92PubMedCrossRefGoogle Scholar
  37. 37.
    Cummings DM, Amadio Jr P, Nelson L, et al. The role of calcium channel blockers in the treatment of essential hypertension. Arch Intern Med 1991; 151: 250–9PubMedCrossRefGoogle Scholar
  38. 38.
    Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326–31PubMedCrossRefGoogle Scholar
  39. 39.
    Fleckenstein A. History and prospects in calcium antagonist research. J Mol Cell Cardiol 1990; 22: 241–51PubMedCrossRefGoogle Scholar
  40. 40.
    Luscher TF, Cosentino F. The classification of calcium antagonists and their selection in the treatment of hypertension. Drugs 1998; 55: 509–17PubMedCrossRefGoogle Scholar
  41. 41.
    Hamada T, Watanabe M, Kaneda T, et al. Evaluation of changes in sympathetic nerve activity and heart rate in essential hypertensive patients induced by amlodipine and nifedipine. J Hypertens 1998; 16: 111–8PubMedCrossRefGoogle Scholar
  42. 42.
    Murdoch D, Heel RC. Amlodipine. Drugs 1991; 41: 478–505PubMedCrossRefGoogle Scholar
  43. 43.
    Hall WD, Reed JW, Flack JM, et al. Comparison of the efficacy of dihydropyridine calcium channel blockers in African American patients with hypertension. Arch Intern Med 1998; 158: 2029–34PubMedCrossRefGoogle Scholar
  44. 44.
    Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly. Lancet 2000; 355: 865–72PubMedCrossRefGoogle Scholar
  45. 45.
    Packer M, O’Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335: 1107–14PubMedCrossRefGoogle Scholar
  46. 46.
    Feigin VL, Rinkel GJE, Algra A, et al. Calcium antagonists in patients with aneurysmal subarachnoid hemorrhage. Neurology 1998; 50: 876–83PubMedCrossRefGoogle Scholar
  47. 47.
    Grossman E, Messerli FH, Grodzicki T, et al. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA 1996; 276: 1328–31PubMedCrossRefGoogle Scholar
  48. 48.
    Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620–5PubMedCrossRefGoogle Scholar
  49. 49.
    Alderman MH, Cohen H, Roqué R, et al. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet 1997; 349: 594–8PubMedCrossRefGoogle Scholar
  50. 50.
    Bailey DG, Dresser GK, Kreeft JH, et al. Grapefruit-felodipine interaction. Clin Pharmacol Ther 2000; 68: 468–77PubMedCrossRefGoogle Scholar
  51. 51.
    Malhotra S, Bailey DG, Paine MF, et al. Seville orange juice-felodipine interaction. Clin Pharmacol Ther 2001; 69: 14–23PubMedCrossRefGoogle Scholar
  52. 52.
    Khatri I, Uemura N, Notargiacomo A, et al. Direct and reflex cardiostimulating effects of hydralazine. Am J Cardiol 1977; 40: 38–42CrossRefGoogle Scholar
  53. 53.
    Ram CVS. Direct vasodilators. In: Hypertension primer. Dallas (TX): American Heart Association, 1999: 385–7Google Scholar
  54. 54.
    Cameron HA, Ramsay LE. The lupus syndrome induced by hydralazine. BMJ 1984; 289: 410–2PubMedCrossRefGoogle Scholar
  55. 55.
    Campese VM. Minoxidil: a review of its pharmacological properties and therapeutic use. Drugs 1981; 22: 257–78PubMedCrossRefGoogle Scholar
  56. 56.
    Ram CVS. Refractory hypertension. In: Weber MA, editor. Hypertension medicine. Totowa (NJ): Humana Press, 2001: 429–36Google Scholar
  57. 57.
    Ram CVS, Fenves A. Hypertension. In: Rakel RE, editor. Conn’s current therapy. Philadelphia (PA): WB Saunders, 2000: 303–14Google Scholar
  58. 58.
    Lundeen TE, Dolan DJ, Ram CV. Pericardial effusion associated with minoxidil therapy. Postgrad Med 1981; 70: 98–100PubMedGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  • C. Venkata S. Ram
    • 1
  1. 1.Texas Blood Pressure Institute, Dallas Nephrology AssociatesThe University of Texas Southwestern Medical Center of DallasDallasUSA

Personalised recommendations